Monitor upcoming FDA action on the cemdisiran application, expected within 10-12 months of submission. The combination of best-in-class efficacy, durable response, and convenient dosing could drive rapid adoption and premium pricing. Investors should also watch for updates on combination trials with pozelimab in PNH and geographic atrophy.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 21 $747.15entry
- T+1 · 7mo ago −0.11%α −1.13% · $746.32
- T+5 · 7mo ago −2.38%α −3.46% · $729.36
- T+20 · 6mo ago −15.72%α −20.64% · $629.68
- T+60 · 4mo ago −9.13%α −15.75% · $678.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Regeneron announced positive Phase 3 NIMBLE trial results for cemdisiran, an investigational siRNA therapy for generalized myasthenia gravis (gMG), demonstrating statistically significant and clinically meaningful improvements in both primary and key secondary endpoints. The company has submitted a U.S. regulatory application and plans European filings in 2026, positioning cemdisiran as a potential first-in-class siRNA treatment for gMG with convenient quarterly dosing.
Key Facts
- Cemdisiran met primary endpoint with a 2.3-point placebo-adjusted improvement in MG-ADL score at week 24 (p<0.001)
- Achieved key secondary endpoint with a 2.8-point placebo-adjusted improvement in QMG score (p=0.002)
- 76.6% of cemdisiran patients had ≥3-point improvement in MG-ADL vs. 44.1% on placebo
- 48.4% of cemdisiran patients had ≥5-point improvement in QMG vs. 19% on placebo
- U.S. regulatory application submitted in Q1 2026; EU filings planned for 2026
- Cemdisiran is a novel siRNA therapeutic allowing for every-three-month subcutaneous dosing
Financial Impact
Potential blockbuster revenue opportunity; gMG affects ~85,000 people in the U.S. with high unmet need
Risk Factors
- Regulatory delay or rejection despite positive data
- Safety concerns related to complement inhibition (e.g., infection risk), particularly given the boxed warning for related drug Veopoz
- Competition from existing C5 inhibitors with established efficacy and safety profiles
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278163 |
Track record
53 reports on REGN
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers